Hematopoietic SCT for mantle cell lymphoma: Is it the standard of care

C. Nabhan*, A. Ragam, J. D. Bitran, J. Mehta

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


The role of hematopoietic SCT (HSCT) in mantle cell lymphoma (MCL) remains controversial. Most studies that support the utility of this approach were small phase II single-institution studies with highly selected patient populations. Furthermore, recent evidence suggesting initial observation as opposed to immediate therapy in MCL, coupled with the availability of newer therapeutic agents, complicates the role of HSCT and argues for conducting large phase III studies. In this review, we discuss the limitation of current evidence and the lack of large definitive studies. We then analyze the data on HSCT in relapsed MCL and as a frontline approach propose applying the new prognostic index, MIPI (MCL International Prognostic Index), in the decision making.

Original languageEnglish (US)
Pages (from-to)1379-1387
Number of pages9
JournalBone Marrow Transplantation
Issue number9
StatePublished - Sep 2010


  • SCT
  • lymphoma
  • mantle cell lymphoma

ASJC Scopus subject areas

  • Transplantation
  • Hematology


Dive into the research topics of 'Hematopoietic SCT for mantle cell lymphoma: Is it the standard of care'. Together they form a unique fingerprint.

Cite this